Status: Not yet recruiting
Hypoxic Red Blood Cells in Sickle Cell Anemia
The overall objective of this study is to evaluate the effectiveness and safety of transfusing hypoxic red blood cells manufactured with the Hemanext ONE system in patients with sickle cell anemia. The Hemanext ONE device was cleared through the De Novo process in September 2023.
Participants needed: 48
Trial details
Age: 7+Biological sex: AllType: InterventionalSponsor: HemanextUpdated: Jan 7, 2026Locations: 6
Eligibility criteria
Male or female at least 7 years of age; [+4]
Are not exclusively transfused at the site; [+9]